Drug Screening Market

The global drug screening market is projected to reach USD 19.5 billion by 2029, from USD 9.1 billion in 2024, at a CAGR of 16.6% during the forecast period. Growth in this market is credited to the growing drug & alcohol consumption leading an increase in impaired driving and the enforcement of stringent laws mandating drug & alcohol testing, rising regulatory approvals for drug screening products & services to curb the growing abuse of drug.

The drug screening market is highly competitive by several big and small players. Prominent players providing drug screening products and services comprise Abbott (US), Thermo Fisher Scientific Inc. (US), Quest Diagnostics (US), Labcorp (US), OraSure Technologies Inc. (US), Alfa Scientific Designs, Inc. (US),  Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd   (Switzerland), MPD Inc. (US), Drägerwerk AG & Co. KGaA (Germany), Shimadzu Corporation (Japan), Lifeloc Technologies, Inc. (US), Clinical Reference Laboratory, Inc. (US), American Bio Medica Corporation (US), ACM Global Laboratories (US), Premier Biotech, Inc. (US), Omega Laboratories, Inc. (US), Psychemedics Corporation (US), Sciteck, Inc. (US), Intoximeters, Inc. (US), CareHealth America Corp (US), AccuSourceHR, Inc. (US), Cordant Health Solutions (US), Intoxalock (US), Millennium nHealth (US).

To know about the assumptions considered for the study download the pdf brochure

Labcorp (US): Labcorp is a leading player in the US drug screening services market that provides clinical laboratory services and drug development solutions. The company operates through two reportable segments—Diagnostics Laboratories (Dx), which includes routine testing and specialty/esoteric testing, and Biopharma Laboratory Services (BLS), consisting of Early Development Research Laboratories and Central Laboratory Services. The company’s Diagnostics Laboratories (Dx) segment offers drug and alcohol testing services. The company has more than 67,000 employees serve clients in over 100 countries, worked on over 84% of the new drugs approved by the FDA in 2023 and executed more than 600 million tests for patients around the world. The company has more than 80,000 employees, serves clients in more than 100 countries. Recently, in 2024 Labcorp announces acquisition of select assets of BioReference Health's diagnostic business expanding access to the company high-quality clinical laboratory services.

Abbott (US): Abbott is one of the global providers of rapid, point of care tests and leader in drug screening market. Abbott operates via five business segments: Established Pharmaceuticals Products, Nutritional Products, Diagnostic Products, & Medical Devices. The Diagnostic products include sales of diagnostic systems tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The company provides drug screening products and services through the diagnostic products segment. The company’s Diagnostics Product is further segmented into Core Laboratory, Rapid Diagnostics, Molecular, and Point of care. The company has a strong presence in North America, Europe, Asia Pacific, Latin America, & Middle East & Africa. The company provide substance abuse testing products and services for a array of settings such as rehabilitation centers,hospitals, criminal justice agencies, physician offices, workplace, and occupational health clinics, and homes.

Related Reports:

Drug Screening Market by Product (Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Urine, Breath, Hair), Drug (Alcohol, Cannabis, Opioids), End User (Workplace, Hospital, Law) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]